MPE
MCID: MYL015
MIFTS: 34

Myeloproliferative Disorder with Eosinophilia (MPE) malady

Categories: Genetic diseases, Blood diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Myeloproliferative Disorder with Eosinophilia

Aliases & Descriptions for Myeloproliferative Disorder with Eosinophilia:

Name: Myeloproliferative Disorder with Eosinophilia 54 24 13
Myeloproliferative Disorder Chronic with Eosinophilia 66 29
Malignant Proliferation of Eosinophils 66 29
Mpe 24 66
Myeloproliferative Disorder, Chronic, with Eosinophilia 54
Chronic Myeloproliferative Disease, Unclassifiable 56
Undifferentiated Myeloproliferative Disease 56
Myeloproliferative Neoplasm, Unclassifiable 69
Eosinophils, Malignant Proliferation of 24
Cmpd-U 56
Emp 24

Characteristics:

HPO:

32
myeloproliferative disorder with eosinophilia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 131440
Orphanet 56 ORPHA86830
ICD10 via Orphanet 34 D47.1
MedGen 40 C1851585

Summaries for Myeloproliferative Disorder with Eosinophilia

UniProtKB/Swiss-Prot : 66 Myeloproliferative disorder chronic with eosinophilia: A hematologic disorder characterized by malignant eosinophils proliferation.

MalaCards based summary : Myeloproliferative Disorder with Eosinophilia, also known as myeloproliferative disorder chronic with eosinophilia, is related to myeloproliferative neoplasm and pdgfrb-associated chronic eosinophilic leukemia, and has symptoms including eosinophilia, myeloproliferative disorder and malignant eosinophil proliferation. An important gene associated with Myeloproliferative Disorder with Eosinophilia is PDGFRB (Platelet Derived Growth Factor Receptor Beta), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Aldesleukin and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include t cells.

Description from OMIM: 131440

Related Diseases for Myeloproliferative Disorder with Eosinophilia

Diseases related to Myeloproliferative Disorder with Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
id Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 11.2
2 pdgfrb-associated chronic eosinophilic leukemia 11.1
3 extramedullary plasmacytoma 10.2
4 plasmacytoma 10.2
5 myofibromatosis, infantile, 1 9.9 IFNA2 PDGFRB
6 may-thurner syndrome 9.9 IFNA2 PDGFRB
7 temporomandibular ankylosis 9.8 IFNA2 PDGFRB
8 bernard-soulier syndrome, type c 9.8 IFNA2 PDGFRB
9 pericardial effusion 9.8
10 adenocarcinoma 9.8
11 erythrocytosis, somatic 9.8 IFNA2 PDGFRB
12 lymphoma 9.8
13 mediastinitis 9.8
14 endotheliitis 9.8
15 peroxisome biogenesis disorder 7a 9.7 IFNA2 PDGFRB

Graphical network of the top 20 diseases related to Myeloproliferative Disorder with Eosinophilia:



Diseases related to Myeloproliferative Disorder with Eosinophilia

Symptoms & Phenotypes for Myeloproliferative Disorder with Eosinophilia

Symptoms by clinical synopsis from OMIM:

131440

Clinical features from OMIM:

131440

Human phenotypes related to Myeloproliferative Disorder with Eosinophilia:

32
id Description HPO Frequency HPO Source Accession
1 eosinophilia 32 HP:0001880
2 myeloproliferative disorder 32 HP:0005547
3 malignant eosinophil proliferation 32 HP:0006782

Drugs & Therapeutics for Myeloproliferative Disorder with Eosinophilia

Drugs for Myeloproliferative Disorder with Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
2
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
3
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
4
Daunorubicin Approved Phase 3 20830-81-3 30323
5
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Lenograstim Approved Phase 3 135968-09-1
7
Asparaginase Approved Phase 3 9015-68-3
8
Thioguanine Approved Phase 3 154-42-7 2723601
9 Bone Density Conservation Agents Phase 3
10 Calcium, Dietary Phase 3
11 Alkylating Agents Phase 3,Phase 2
12 Analgesics Phase 3,Phase 2,Phase 1
13 Analgesics, Non-Narcotic Phase 3
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Anti-HIV Agents Phase 3
17 Anti-Infective Agents Phase 3,Phase 2,Phase 1
18 Antimetabolites Phase 3,Phase 2,Phase 1
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
22 Anti-Retroviral Agents Phase 3
23 Antiviral Agents Phase 3,Phase 2,Phase 1
24 Etoposide phosphate Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Interleukin-2 Phase 3
27 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
29
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
30
Vidarabine Approved Phase 2 24356-66-9 32326 21704
31
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
32
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
33
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
34
Ondansetron Approved Phase 2 99614-02-5 4595
35
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
36
Idarubicin Approved Phase 2,Phase 1 58957-92-9 42890
37
Lenalidomide Approved Phase 2 191732-72-6 216326
38
Mitoxantrone Approved, Investigational Phase 2,Phase 1 65271-80-9 4212
39
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
40
Mycophenolic acid Approved Phase 2 24280-93-1 446541
41
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
44
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
45
tipifarnib Investigational Phase 1, Phase 2 192185-72-1 159324
46 Imatinib Mesylate Phase 2,Phase 1 123596
47 Protein Kinase Inhibitors Phase 2,Phase 1
48 Vidarabine Phosphate Phase 2
49 Anti-Asthmatic Agents Phase 2
50 Anti-Inflammatory Agents Phase 2

Interventional clinical trials:

(show all 48)
id Name Status NCT ID Phase
1 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
2 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3
3 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3
4 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3
5 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2
6 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2
7 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2
8 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2
9 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2
10 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2
11 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2
12 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2
13 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2
14 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2
15 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2
16 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2
17 SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) Recruiting NCT02268253 Phase 1, Phase 2
18 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2
19 Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy Recruiting NCT02071901 Phase 2
20 Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated NCT00096148 Phase 2
21 Cilengitide in Treating Patients With Acute Myeloid Leukemia Terminated NCT00089388 Phase 2
22 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders Completed NCT00357305 Phase 1
23 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1
24 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1
25 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Completed NCT01484015 Phase 1
26 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Completed NCT00025415 Phase 1
27 XK469R in Treating Patients With Refractory Hematologic Cancer Completed NCT00095797 Phase 1
28 Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes Completed NCT00098423 Phase 1
29 Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Completed NCT00131989 Phase 1
30 Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Completed NCT00383474 Phase 1
31 Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00217646 Phase 1
32 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
33 Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia Terminated NCT01550185 Phase 1
34 Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia Terminated NCT01159301 Phase 1
35 Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Terminated NCT00101231 Phase 1
36 Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Terminated NCT01260714 Phase 1
37 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer Terminated NCT00103272 Phase 1
38 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant Completed NCT00408681
39 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer Completed NCT01233921
40 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Completed NCT01199562
41 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593
42 Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate Completed NCT00038675
43 Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia Completed NCT01076569
44 Myeloproliferative Neoplasms (MPNs) Patient Registry Recruiting NCT02760238
45 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders Active, not recruiting NCT00856388
46 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer Active, not recruiting NCT01053494
47 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067
48 Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant Withdrawn NCT01558778

Search NIH Clinical Center for Myeloproliferative Disorder with Eosinophilia

Genetic Tests for Myeloproliferative Disorder with Eosinophilia

Genetic tests related to Myeloproliferative Disorder with Eosinophilia:

id Genetic test Affiliating Genes
1 Myeloproliferative Disorder, Chronic, with Eosinophilia 29
2 Malignant Eosinophil Proliferation 29
3 Myeloproliferative Disorder with Eosinophilia 24 PDGFRB

Anatomical Context for Myeloproliferative Disorder with Eosinophilia

MalaCards organs/tissues related to Myeloproliferative Disorder with Eosinophilia:

39
T Cells

Publications for Myeloproliferative Disorder with Eosinophilia

Articles related to Myeloproliferative Disorder with Eosinophilia:

id Title Authors Year
1
Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib. ( 22488677 )
2012
2
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. ( 19394693 )
2009
3
Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. ( 10741923 )
2000
4
Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12) ( 9639434 )
1998
5
A myeloproliferative disorder with eosinophilia associated with a unique translocation (3;5). ( 8943895 )
1996

Variations for Myeloproliferative Disorder with Eosinophilia

Expression for Myeloproliferative Disorder with Eosinophilia

Search GEO for disease gene expression data for Myeloproliferative Disorder with Eosinophilia.

Pathways for Myeloproliferative Disorder with Eosinophilia

Pathways related to Myeloproliferative Disorder with Eosinophilia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.07 IFNA2 PDGFRB
2 11.16 IFNA2 PDGFRB

GO Terms for Myeloproliferative Disorder with Eosinophilia

Sources for Myeloproliferative Disorder with Eosinophilia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....